NewsAvi Kapoor
Design Therapeutics
DSGN · NASDAQ
$11.10+$0.46 (+4.32%)TodayMarket closed ·
Prev close $10.64
Latest news
- Press releaseGlobe Newswire
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
- NewsAvi Kapoor
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May
- NewsAvi Kapoor
Nasdaq Down 200 Points; Brady Earnings Top Views
- Press releaseGlobe Newswire
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
- NewsAvi Kapoor
Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock
- NewsAvi Kapoor
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
- Press releaseGlobe Newswire
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
- NewsAvi Kapoor
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday
- News
Design Therapeutics Gets Clearance To Start Dosing DM1 Participants In Phase 1 Multiple-Ascending Dose Study Of DT-818 In Australia In H1 2026
- Press releaseGlobe Newswire
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
- Press releaseGlobe Newswire
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.